微芯生物2024年度业绩快报：归母净利润为-1.15亿元同比减少228.97%

财中社2025-02-27

2月27日，微芯生物（688321）发布公告，2024年度业绩快报显示，公司营业总收入为6.58亿元，同比增长25.63%。主要增长原因是公司产品西达本胺和西格列他钠销量大幅提升。然而，归母净利润为-1.15亿元，同比减少228.97%；归母净利润扣除非经常性损益后为-2.05亿元，同比减亏5.62%。基本每股收益为-0.2808元，同比下降229.04%。公告中提到，公司与浙江海正药业提前终止了...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2514877125?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-02-27 18:51","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2514877125","market":"sh","top_or_hot":-1,"title":"微芯生物2024年度业绩快报：归母净利润为-1.15亿元 同比减少228.97%","media":"财中社","content":"<div>\n<p>2月27日，微芯生物（688321）发布公告，2024年度业绩快报显示，公司营业总收入为6.58亿元，同比增长25.63%。主要增长原因是公司产品西达本胺和西格列他钠销量大幅提升。然而，归母净利润为-1.15亿元，同比减少228.97%；归母净利润扣除非经常性损益后为-2.05亿元，同比减亏5.62%。基本每股收益为-0.2808元，同比下降229.04%。公告中提到，公司与浙江海正药业提前终止了...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227185320963272df&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>微芯生物2024年度业绩快报：归母净利润为-1.15亿元 同比减少228.97%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n微芯生物2024年度业绩快报：归母净利润为-1.15亿元 同比减少228.97%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-02-27 18:51 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227185320963272df&s=b><strong>财中社</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>2月27日，微芯生物（688321）发布公告，2024年度业绩快报显示，公司营业总收入为6.58亿元，同比增长25.63%。主要增长原因是公司产品西达本胺和西格列他钠销量大幅提升。然而，归母净利润为-1.15亿元，同比减少228.97%；归母净利润扣除非经常性损益后为-2.05亿元，同比减亏5.62%。基本每股收益为-0.2808元，同比下降229.04%。公告中提到，公司与浙江海正药业提前终止了...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227185320963272df&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"688321","symbol_name":"微芯生物","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227185320963272df&s=b","article_id":"2514877125","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227185320963272df&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2514877125","pubTimestamp":1740653500,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"2月27日，微芯生物发布公告，2024年度业绩快报显示，公司营业总收入为6.58亿元，同比增长25.63%。主要增长原因是公司产品西达本胺和西格列他钠销量大幅提升。然而，归母净利润为-1.15亿元，同比减少228.97%；归母净利润扣除非经常性损益后为-2.05亿元，同比减亏5.62%。基本每股收益为-0.2808元，同比下降229.04%。整体来看，尽管营业收入实现增长，归母净利润的显著下降反映出公司面临的挑战。2024年前三季度，微芯生物实现收入4.81亿元，归母净利润-5108万元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"688321":"微芯生物"},"translate_title":"Microchip Biotech's 2024 annual performance report: Net profit attributable to the parent company was-115 million yuan, a year-on-year decrease of 228.97%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688321":1},"content_text":"2月27日，微芯生物（688321）发布公告，2024年度业绩快报显示，公司营业总收入为6.58亿元，同比增长25.63%。主要增长原因是公司产品西达本胺和西格列他钠销量大幅提升。然而，归母净利润为-1.15亿元，同比减少228.97%；归母净利润扣除非经常性损益后为-2.05亿元，同比减亏5.62%。基本每股收益为-0.2808元，同比下降229.04%。公告中提到，公司与浙江海正药业提前终止了西格列他钠片的独占许可及联合营销战略合作协议，确认收益约8200万元。同时，由于临床试验结果及诊疗实践变化，公司决定不再递交西奥罗尼单药治疗小细胞肺癌的上市申请，相应计提资产减值准备约9000万元，影响了利润总额的减少。整体来看，尽管营业收入实现增长，归母净利润的显著下降反映出公司面临的挑战。2024年前三季度，微芯生物实现收入4.81亿元，归母净利润-5108万元。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2514877125","isCrawlerRequest":true}

微芯生物2024年度业绩快报：归母净利润为-1.15亿元 同比减少228.97%

精彩评论

微芯生物2024年度业绩快报：归母净利润为-1.15亿元同比减少228.97%